Author:
Shubina Irina Zh,Titov Konstantin S.,Chikileva Irina O.,Demidov Lev V.,Kiselevsky Mikhail V.
Reference56 articles.
1. Allan SE, Crome SQ, Crellin NK et al (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354
2. Antonov AK, Titov KS, Belousov AV, Kiselevsky MV (2011) Treatment of malignant pericardites. Vest Sluzhby Krovi 2:27–29
3. Antony PA, Restifo NP (2005) CD4 + CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28:120–128
4. Bindon C, Czerniecki M, Ruell P et al (1983) Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47:123–133
5. Blanchard DK, Kavanagh JJ, Sinkovics JG (1988) Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res 48:6321–6327